Simone Breiteneicher
Overview
Explore the profile of Simone Breiteneicher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koletzko S, Le Thi T, Zhelyazkova A, Osterman A, Wichert S, Breiteneicher S, et al.
Clin Exp Med
. 2023 Sep;
23(8):4901-4917.
PMID: 37659994
The primary objective of the RisCoin study was to investigate the interplay of genetic, metabolic, and lifestyle factors as well as stress levels on influencing the humoral immune response after...
2.
Koletzko L, Klucker E, Le Thi T, Breiteneicher S, Rubio-Acero R, Neuhaus L, et al.
J Clin Med
. 2021 Sep;
10(18).
PMID: 34575235
Background: COVID-19-associated restrictions impact societies. We investigated the impact in a large cohort of inflammatory bowel disease (IBD) patients. Methods: Pediatric (pIBD) and adult patients and pIBD parents completed validated...
3.
Unterweger A, Ruscher A, Seuss M, Winkelmann P, Beigel F, Koletzko L, et al.
Immun Inflamm Dis
. 2021 Sep;
9(4):1631-1647.
PMID: 34499803
Introduction: Crohn's disease (CD) is characterized by pronounced intestinal fibrosis and severe mucosal damage and conventional animal models are limited to reflect these pathological manifestations. The aim of this study...
4.
Jodeleit H, Winkelmann P, Caesar J, Sterz S, Holdt L, Beigel F, et al.
Dis Model Mech
. 2020 Dec;
14(1).
PMID: 33293281
This study's aim was to demonstrate that the combination of patient immune profiling and testing in a humanized mouse model of ulcerative colitis (UC) might lead to patient stratification for...
5.
Jodeleit H, Caesar J, Villarroel Aguilera C, Sterz S, Holdt L, Beigel F, et al.
Inflamm Bowel Dis
. 2019 Nov;
26(4):557-569.
PMID: 31782956
Background: To date, responsiveness to tumor necrosis factor alpha inhibitors in ulcerative colitis (UC) patients is not predictable. This is partially due to a lack of understanding of the underlying...
6.
Beigel F, Teich N, Howaldt S, Lammert F, Maul J, Breiteneicher S, et al.
J Crohns Colitis
. 2014 Jun;
8(11):1471-9.
PMID: 24953836
Background And Aims: Bile acid malabsorption (BAM)-associated diarrhea is an important clinical issue in patients with Crohn's disease (CD). We analyzed the efficacy and safety of the bile acid sequestrant...
7.
Beigel F, Deml M, Schnitzler F, Breiteneicher S, Goke B, Ochsenkuhn T, et al.
PLoS One
. 2014 Jun;
9(6):e99293.
PMID: 24932476
Objective: Mucosal healing (MH) is an important treatment goal in patients with inflammatory bowel disease (IBD), but factors predicting MH under medical therapy are largely unknown. In this study, we...
8.
Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John J, et al.
Pharmacoepidemiol Drug Saf
. 2014 May;
23(7):735-44.
PMID: 24788825
Purpose: We aimed to analyse malignancy rates and predictors for the development of malignancies in a large German inflammatory bowel disease (IBD) cohort treated with thiopurines and/or anti-tumour necrosis factor...
9.
Beigel F, Lohr B, Laubender R, Tillack C, Schnitzler F, Breiteneicher S, et al.
Digestion
. 2011 Dec;
85(1):47-54.
PMID: 22179489
Background And Aims: We analyzed iron deficiency and the therapeutic response following intravenous ferric carboxymaltose in a large single-center inflammatory bowel disease (IBD) cohort. Methods: 250 IBD patients were retrospectively...